Related Experiment Video
Updated: Jun 2, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Current status of drug therapy for chronic hepatitis B
Chuang Jiang1, Zhi-Hong Zhang1, Jia-Xin Li1,2
1Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
Insights
Chronic hepatitis B (CHB) treatment effectively controls Hepatitis B virus (HBV) replication but cannot eliminate it. Evaluating antiviral drug safety and efficacy is crucial for managing long-term treatment and improving patient outcomes.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B (CHB) is a major global health concern, especially in developing nations.
- Hepatitis B virus (HBV) infection is a primary risk factor for cirrhosis and hepatocellular carcinoma.
- Effective prevention and treatment of HBV are vital for reducing disease complications.
Abstract:
In this editorial, we comment on the article by Meng et al. Chronic hepatitis B (CHB) is a significant global health problem, particularly in developing countries. Hepatitis B virus (HBV) infection is one of the most important risk factors for cirrhosis and hepatocellular carcinoma. Prevention and treatment of HBV are key measures to reduce complications. At present, drug therapy can effectively control virus replication and slow disease progression, but completely eliminating the virus remains a challenge. Anti-HBV treatment is a long-term process, and there are many kinds of antiviral drugs with different mechanisms of action, it is essential to evaluate the safety and efficacy of these drugs to reduce side effects and improve patients' compliance. We will summarize the current status of CHB drug treatment, hoping to provide a reference for the selection of clinical antiviral drugs.
More Related Videos
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Retrovirus Life Cycles
Drug Therapy
Antianxiety Medications
Hepatic Drug Clearance: Role of Transporters
Hepatic Drug Excretion: Influencing Factors
Chronic Pancreatitis II: Collaborative Care
Assessment: